Treating Hodgkin lymphoma in the new millennium: Relapsed and refractory disease
- PMID: 31187532
- DOI: 10.1002/hon.2589
Treating Hodgkin lymphoma in the new millennium: Relapsed and refractory disease
Abstract
Although the majority of patients with Hodgkin lymphoma are cured with initial therapy, 10% to 15% of patients with early stage disease and 15% to 30% of patients with advanced disease have primary refractory or relapsed lymphoma. For younger patients whose disease is sensitive to second-line therapy, more than half of patients will experience long-term disease control with high-dose chemotherapy/autologous stem cell rescue (ASCT). For those patients who are chemotherapy refractory, relapse after, or are ineligible for ASCT, brentuximab vedotin, and checkpoint, inhibitors are highly active, although the majority of patients will ultimately experience recurrent lymphoma. Allogeneic transplant is curative in a subset of patients but may be associated with significant toxicity. Novel targeted and immunotherapy approaches, including chimeric antigen receptor T-cell therapy, are currently being studied in clinical trials with promising early results.
© 2019 John Wiley & Sons, Ltd.
Similar articles
-
Relapsed and Refractory Classical Hodgkin Lymphoma: Keeping Pace With Novel Agents and New Options for Salvage Therapy.Am Soc Clin Oncol Educ Book. 2019 Jan;39:477-486. doi: 10.1200/EDBK_238799. Epub 2019 May 17. Am Soc Clin Oncol Educ Book. 2019. PMID: 31099645 Review.
-
Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study.Eur J Haematol. 2017 Dec;99(6):553-558. doi: 10.1111/ejh.12973. Epub 2017 Oct 16. Eur J Haematol. 2017. PMID: 28949403
-
Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: A real-life experience.Hematol Oncol. 2020 Dec;38(5):737-741. doi: 10.1002/hon.2803. Epub 2020 Sep 30. Hematol Oncol. 2020. PMID: 32905626
-
Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors.Ann Hematol. 2018 Aug;97(8):1301-1315. doi: 10.1007/s00277-018-3366-x. Epub 2018 May 25. Ann Hematol. 2018. PMID: 29802458 Review.
-
Immunotherapy for the treatment of Hodgkin lymphoma.Expert Rev Hematol. 2017 May;10(5):417-423. doi: 10.1080/17474086.2017.1313701. Epub 2017 Apr 12. Expert Rev Hematol. 2017. PMID: 28359170 Review.
Cited by
-
Unveiling the Role of the Tumor Microenvironment in the Treatment of Follicular Lymphoma.Cancers (Basel). 2022 Apr 26;14(9):2158. doi: 10.3390/cancers14092158. Cancers (Basel). 2022. PMID: 35565286 Free PMC article. Review.
-
Methodological framework for radiomics applications in Hodgkin's lymphoma.Eur J Hybrid Imaging. 2020 Jun 1;4(1):9. doi: 10.1186/s41824-020-00078-8. Eur J Hybrid Imaging. 2020. PMID: 34191173 Free PMC article.
-
Immune-Proteome Profiling in Classical Hodgkin Lymphoma Tumor Diagnostic Tissue.Cancers (Basel). 2021 Dec 21;14(1):9. doi: 10.3390/cancers14010009. Cancers (Basel). 2021. PMID: 35008176 Free PMC article.
-
Real-world evidence of ABVD-like regimens compared with ABVD in classical Hodgkin lymphoma: a 10-year study from China.J Cancer Res Clin Oncol. 2023 Jul;149(7):3989-4003. doi: 10.1007/s00432-022-04321-6. Epub 2022 Aug 28. J Cancer Res Clin Oncol. 2023. PMID: 36030432 Free PMC article.
-
Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy.Oncologist. 2020 Oct;25(10):878-885. doi: 10.1634/theoncologist.2020-0167. Epub 2020 Aug 28. Oncologist. 2020. PMID: 32720734 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical